ReAlta Life Sciences, Inc.
ReAlta Life Sciences, Inc.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypoxia, Hypoxia, Brain, Infant, Newborn, Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Respiratory, brain disorder, brain hypoxia - ischemia, brain ischemia, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, nervous system disorder, perinatal asphyxia, vascular disorder | Recruiting | Phase 2 | 2026-04-13 | NCT05778188 | |
| Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease | Steroid Refractory GVHD | Recruiting | Phase 2 | 2025-11-24 | NCT06343792 | |
| Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease | Acute Exacerbation of Chronic Obstructive Pulmonary Disease | Active, not recruiting | Phase 2 | 2025-05-08 | NCT06175065 |